New Metrics For Clinical Trial Oversight Floated By CDRH Entrepreneurs In Residence
This article was originally published in The Gray Sheet
Executive Summary
Variability runs high in FDA’s process for approving new device trials, but the agency is open to recommendations for improvements coming out of its entrepreneurs-in-residence program, says Chip Hance, a former Abbott executive participating in the program.
You may also be interested in...
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
CDRH’s Shuren Signals More Guidance, Enhanced Pre-Market Payer Role
CDRH Director Jeffrey Shuren details plans for new guidance documents and process changes at the device center, focused on IDE reviews, clinical testing requirements and pre-submission interactions with payers based on recommendations from the center’s entrepreneurs-in-residence program.